

- 1: Pinto-Medel MJ, Oliver-Martos B, Urbaneja-Romero P, Hurtado-Guerrero I, Ortega-Pinazo J, Serrano-Castro P, **Fernández Ó**, Leyva L. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNβ treatment. *Sci Rep*. 2017 Aug 18;7(1):8727. doi:10.1038/s41598-017-09301-2. PubMed PMID: 28821874; PubMed Central PMCID:PMC5562733.
- 2: Alvarenga MP, **Fernandez O**, Leyva L, Campanella L, Vasconcelos CF, Alvarenga M, Papais Alvarenga RM. The HLA DRB1\*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro. *J Neuroimmunol*. 2017 Sep 15;310:1-7. doi: 10.1016/j.jneuroim.2017.05.018. Epub 2017 May 31. PubMed PMID: 28778431.
- 3: **Fernández Ó**, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. *Clin Ther*. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25. PubMed PMID: 28751099.
- 4: **Fernández O**, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F. Estimate of the cost of multiple sclerosis in Spain by literature review. *Expert Rev Pharmacoecon Outcomes Res*. 2017 Aug;17(4):321-333. doi:10.1080/14737167.2017.1358617. Epub 2017 Jul 28. Review. PubMed PMID:28726515.
- 5: **Fernandez O**, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Oliva-Nacarino P, Calles-Hernandez MC, Izquierdo G, Martinez-Gines ML, Saiz A, Comabella M, Casanova-Estruch B, Brieva L, Arroyo R, Rodriguez-Antigüedad A. Review of the novelties from the 32ndECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I). *Rev Neurol*. 2017 Jul 1;65(1):31-40. Review. Spanish, English. PubMed PMID: 28650065.
- 6: Munoz-Ruiz T, Fernandez-Sanchez VE, Reyes-Garrido V, Martinez-Tomas C, Urbaneja-Romero P, Gallardo-Tur A, Guerrero-Fernandez M, Leon-Martin A, **Fernandez O**. [Transcultural validation in Spanish of the Actionable Bladder Symptoms Screening Tool]. *Rev Neurol*. 2017 May 1;64(9):401-406. Spanish. PubMed PMID: 28444682.
- 7: Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, **Fernández O**, Alvarez-Lafuente R, Arroyo R, Castro A. Metabolomic signatures associated with disease severity in multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2017 Jan 27;4(2):e321. doi: 10.1212/NXI.0000000000000321. eCollection 2017 Mar. PubMed PMID: 28180139; PubMed Central PMCID: PMC5278923.
- 8: **Fernández O**, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G. Survey of diagnostic and treatment practices for multiple sclerosis in Europe. *Eur J Neurol*. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31. PubMed PMID: 28139062.
- 9: Duque P, Oltra-Cucarella J, **Fernandez O**, Sepulcre J, Grupo de Estudio de la Bateria Neuropsicologica Breve En la Esclerosis Multiple GE. [Brief Neuropsychological Battery for multiple sclerosis. Normative data stratified by age and educational level]. *Rev Neurol*. 2017 Feb 1;64(3):97-104. Spanish. PubMed PMID: 28128426.
- 10: Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, León A, Guerrero M, **Fernández Ó**, Leyva L, Oliver-Martos B. Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNβ in Multiple Sclerosis Patients According to the Therapeutic Response to IFNβ. *PLoS One*. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017. PubMed PMID: 28103257; PubMed Central PMCID: PMC5245989.
- 11: Marin-Bañasco C, Benabdellah K, Melero-Jerez C, Oliver B, Pinto-Medel MJ, Hurtado-Guerrero I, de Castro F, Clemente D, **Fernández O**, Martin F, Leyva L, Suardiáz M. Gene therapy with mesenchymal stem cells expressing IFN-β ameliorates neuroinflammation in

experimental models of multiple sclerosis. *Br J Pharmacol.* 2017 Feb;174(3):238-253. doi: 10.1111/bph.13674. Epub 2017 Jan 12. PubMed PMID: 27882538; PubMed Central PMCID: PMC5241389.

12: Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodríguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, **Fernández Ó**, Oliver-Martos B. Decreased soluble IFN- $\beta$  receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. *Mult Scler.* 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9. PubMed PMID: 27613121.

13: **Fernández O**, Arroyo R, Martínez-Yélamos S, Marco M, Merino JA, Muñoz D, Merino E, Roque A; RELOAD Study Group. Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis. *PLoS One.* 2016 Aug 15;11(8):e0160313. doi: 10.1371/journal.pone.0160313. eCollection 2016. PubMed PMID: 27526201; PubMed Central PMCID: PMC4985132.

14: van Pesch V, Sindic CJ, **Fernández O**. Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. *Clin Neurol Neurosurg.* 2016 Oct;149:55-63. doi: 10.1016/j.clineuro.2016.07.001. Epub 2016 Jul 14. Review. PubMed PMID: 27475049.

15: Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, Ramio-Torrenta L, Diaz RM, Arroyo R, Urbaneja P, **Fernandez O**, Garcia-Merino JA, Reyes MP, Oreja-Guevara C, Prieto JM, Izquierdo G, Olascoaga J, Alvarez-Cermeño JC, Simon E, Pujal B, Comabella M, Montalban X. [Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score]. *Rev Neurol.* 2016 Aug 16;63(4):145-50. Spanish. PubMed PMID: 27439483.

16: **Fernandez O**, Rodriguez-Antigüedad A, Olascoaga J, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Saiz A, Calles-Hernandez MC, Izquierdo G, Villar LM, Oliva-Nacarino P, Arnal-Garcia C, Comabella M, Brieua L, Arroyo R, Montalban X. Review of the novelties from the 31stECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. *Rev Neurol.* 2016 Jun 16;62(12):559-69. Review. English, Spanish. PubMed PMID: 27270678.

17: Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandebroek K, Akkad DA, Aktas O, Blaschke P, Buttman M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, **Fernandez O**, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C. Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. *G3 (Bethesda).* 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841. PMID: 27194806; PubMed Central PMCID: PMC4938660.

18: **Fernández Ó**. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain. *Eur Neurol.* 2016;75 Suppl 1:1-3. doi: 10.1159/000444234. Epub 2016 Feb 23. Review. PubMed PMID: 26901342.

19: Ramió-Torrentà L, Álvarez-Cermeño JC, Arroyo R, Casanova-Estruch B, **Fernández O**, García-Merino JA, Hernández MA, Izquierdo G, Martínez-Yélamos S, Meca J, Moral E, Olascoaga J, Prieto JM, Saiz A. A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis. *Neurologia.* 2016 Feb 9. pii: S0213-4853(15)00269-8. doi: 10.1016/j.nrl.2015.11.013. [Epub ahead of print] English, Spanish. PubMed PMID: 26873645.

20: Órpez-Zafra T, Pavía J, Pinto-Medel MJ, Hurtado-Guerrero I, Rodríguez-Bada JL, Martín Montañez E, **Fernández Ó**, Leyva L, Oliver-Martos B. Development and validation of an ELISA

for quantification of soluble IFN- $\beta$  receptor: assessment in multiple sclerosis. *Bioanalysis*. 2015;7(22):2869-80. doi: 10.4155/bio.15.208. Epub 2015 Nov 16. PubMed PMID: 26571364.

21: Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova OO, Fedetz M, **Fernández O**, García-Martínez A, Gerdes LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Courneu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandebroek K, Filipenko M, Matesanz F, Zipp F, Bertram L. Genome-wide significant association with seven novel multiple sclerosis risk loci. *J Med Genet*. 2015 Dec;52(12):848-55. doi: 10.1136/jmedgenet-2015-103442. Epub 2015 Oct 16. PubMed PMID: 26475045.

22: Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, **Fernández O**, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandebroek K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M. Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN- $\beta$ . *Neurol Neuroimmunol Neuroinflamm*. 2015 Sep 24;2(5):e154. Doi 10.1212/NXI.000000000000154. eCollection 2015 Oct. PubMed PMID: 26445728; PubMed Central PMCID: PMC4582905.

23: Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, **Fernandez O**, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial. *Neurol Neuroimmunol Neuroinflamm*. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.000000000000147. eCollection 2015 Oct. PubMed PMID: 26405686; PubMed Central PMCID: PMC4567455.

24: **Fernandez O**, Alvarez-Cermeño JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antigüedad A, Saiz A, Tintore M, Grupo Post-Ectrimis GP. [Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7<sup>th</sup> Post-ECTRIMS meeting (I)]. *Rev Neurol*. 2015 Sep 1;61(5):215-24. Spanish. PubMed PMID: 26308843.

25: Matesanz F, Potenciano V, Fedetz M, Ramos-Mozo P, Abad-Grau Mdel M, Karaky M, Barrionuevo C, Izquierdo G, Ruiz-Peña JL, García-Sánchez MI, Lucas M, **Fernández Ó**, Leyva L, Otaegui D, Muñoz-Culla M, Olascoaga J, Vandebroek K, Alloza I, Astobiza I, Antigüedad A, Villar LM, Álvarez-Cermeño JC, Malhotra S, Comabella M, Montalban X, Saiz A, Blanco Y, Arroyo R, Varadé J, Urcelay E, Alcina A. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis. *Hum Mol Genet*. 2015 Oct 1;24(19):5619-27. doi: 10.1093/hmg/ddv256. Epub 2015 Jul 7. PubMed PMID: 26152201.

26: López-Gómez C, Oliver-Martos B, Pinto-Medel MJ, Suardiaz M, Reyes-Garrido V, Urbaneja P, **Fernández Ó**, Leyva L. TRAIL and TRAIL receptors splice variants during long-term interferon  $\beta$  treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response. *J Neurol Neurosurg Psychiatry*. 2016 Feb;87(2):130-7. doi: 10.1136/jnnp-2014-309932. Epub 2015 Mar 3. PubMed PMID: 25736057; PubMed Central PMCID: PMC4752633.

- 27: **Fernández Ó.** [Future challenges in multiple sclerosis]. *Med Clin (Barc)*. 2014 Dec;143 Suppl 3:44-7. doi: 10.1016/S0025-7753(15)30010-5. Review. Spanish. PubMed PMID: 25732950.
- 28: Lopez de Lapuente A, Pinto-Medel MJ, Astobiza I, Alloza I, Comabella M, Malhotra S, Montalban X, Zettl UK, Rodríguez-Antigüedad A, **Fernández O**, Vandenberg K. Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis. *Mult Scler*. 2015 Oct;21(12):1498-512. doi: 10.1177/1352458514566418. Epub 2015 Jan 26. Erratum in: *Mult Scler*. 2016 Jan;22(1):NP5. PubMed PMID: 25623250.
- 29: Malhotra S, Río J, Urcelay E, Nurtdinov R, Bustamante MF, **Fernández O**, Oliver B, Zettl U, Brassat D, Killestein J, Lechner-Scott J, Drulovic J, Chan A, Martinelli-Boneschi F, García-Merino A, Montalban X, Comabella M. NLRP3 inflammasome is associated with the response to IFN- $\beta$  in patients with multiple sclerosis. *Brain*. 2015 Mar;138(Pt 3):644-52. doi: 10.1093/brain/awu388. Epub 2015 Jan 12. PubMed PMID: 25586466; PubMed Central PMCID: PMC4408432.
- 30: Villar LM, Costa-Frossard L, Masterman T, **Fernandez O**, Montalban X, Casanova B, Izquierdo G, Coret F, Tuman H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufríu S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. *Ann Neurol*. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30. PubMed PMID: 25581547.
- 31: de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar LM, Alvarez-Cermeño JC, Izquierdo G, **Fernández O**, Oliver B, Saiz A, Ara JR, Vigo AG, Arroyo R, Meca V, Malhotra S, Fissolo N, Horga A, Montalban X, Comabella M. Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. *Neurol Neuroimmunol Neuroinflamm*. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047. eCollection 2014 Dec. PubMed PMID: 25520955; PubMed Central PMCID: PMC4268037.
- 32: Delgado-García M, Matesanz F, Alcina A, Fedetz M, García-Sánchez MI, Ruiz-Peña JL, **Fernández Ó**, Pinto Medel MJ, Leyva L, Arnal C, Delgado C, López Guerrero JA, González-Pérez A, Sáez ME, Villar LM, Álvarez-Cermeño JC, Picón C, Arroyo R, Varadé J, Urcelay E, Izquierdo G, Lucas M. A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands. *Mult Scler*. 2015 Aug;21(9):1104-11. doi: 10.1177/1352458514556302. Epub 2014 Nov 12. PubMed PMID: 25392328.
- 33: **Fernández O.** Advances in the management of MS spasticity: recent observational studies. *Eur Neurol*. 2014;72 Suppl 1:12-4. doi: 10.1159/000367618. Epub 2014 Sep 26. PubMed PMID: 25278118.
- 34: **Fernández O.** Advances in the management of multiple sclerosis spasticity: recent clinical trials. *Eur Neurol*. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26. PubMed PMID: 25278117.
- 35: **Fernandez O**, Alvarez-Cermeño JC, Arnal-Garcia C, Arroyo-Gonzalez R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Prieto JM, Ramio-Torrenta L, Romero-Pinel L, Saiz A, Rodriguez-Antigüedad A, Grupo Post-Ectrimis GP. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). *Rev Neurol*. 2014 Sep 16;59(6):269-80. Review. English, Spanish. PubMed PMID: 25190340.

- 36: Espiño M, Abraira V, Arroyo R, Bau L, Cámara C, Campos-Ruiz L, Casanova B, Espejo C, **Fernández O**, García-Merino A, García-Sánchez MI, Gómez M, Gosis A, Izquierdo G, Meca J, Montalban X, Morandeira F, Olascoaga J, Prada A, Quintana E, Ramió-Torrentà L, Rodríguez-Antigüedad A, Salgado G, Santiago JL, Sarasola E, Simó-Castelló M, Alvarez-Cermeño JC, Villar LM. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. *Clin Chim Acta*. 2015 Jan 1;438:67-9. doi: 10.1016/j.cca.2014.08.004. Epub 2014 Aug 8. PubMed PMID: 25110815.
- 37: **Fernandez O**, Martin R, Rovira A, Llufríu S, Vidal-Jordana A, Fernandez-Sanchez VE, Alvarez-Cermeño JC, Izquierdo G, Arroyo-Gonzalez R, Rodriguez-Antigüedad A, Casanova-Estruch B, Montalban X. Biomarkers in multiple sclerosis: an update for 2014. *Rev Neurol*. 2014 Jun 16;58(12):553-70. Review. English, Spanish. PubMed PMID: 24915032.
- 38: Villar LM, Casanova B, Ouamara N, Comabella M, Jalili F, Leppert D, de Andrés C, Izquierdo G, Arroyo R, Avşar T, Lapin SV, Johnson T, Montalbán X, **Fernández O**, Álvarez-Lafuente R, Masterman D, García-Sánchez MI, Coret F, Siva A, Evdoshenko E, Álvarez-Cermeño JC, Bar-Or A. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. *Ann Neurol*. 2014 Aug;76(2):231-40. doi: 10.1002/ana.24190. Epub 2014 Jul 2. PubMed PMID: 24909126.
- 39: Núñez C, Cénit MC, Alvarez-Lafuente R, Río J, Fernández-Arquero M, Arroyo R, Montalbán X, **Fernández O**, Oliver-Martos B, Leyva L, Comabella M, Urcelay E. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- $\beta$  therapy in multiple sclerosis. *J Med Genet*. 2014 Jun;51(6):395-400. doi: 10.1136/jmedgenet-2014-102348. Epub 2014 Apr 19. PubMed PMID: 24748646.
- 40: **Fernandez O**. Alemtuzumab in the treatment of multiple sclerosis. *J Inflamm Res*. 2014 Feb 12;7:19-27. doi: 10.2147/JIR.S38079. eCollection 2014. Review. PubMed PMID: 24672254; PubMed Central PMCID: PMC3959804.
- 41: Olsson T, Boster A, **Fernández Ó**, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. *J Neurol Neurosurg Psychiatry*. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. PubMed PMID: 24659797; PubMed Central PMCID: PMC4215282.
- 42: García-León JA, López-Gómez C, Orpez-Zafra T, Reyes-Garrido V, Marín-Bañasco C, Oliver-Martos B, **Fernández O**, Leyva L. Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon- $\beta$ : evaluation as biomarkers for clinical response. *CNS Drugs*. 2014 Jun;28(6):559-70. doi: 10.1007/s40263-014-0153-7. PubMed PMID: 24599774.
- 43: de la Hera B, Varadé J, García-Montojo M, Alcina A, Fedetz M, Alloza I, Astobiza I, Leyva L, **Fernández O**, Izquierdo G, Antigüedad A, Arroyo R, Álvarez-Lafuente R, Vandebroek K, Matesanz F, Urcelay E. Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysis. *PLoS One*. 2014 Mar 3;9(3):e90182. doi: 10.1371/journal.pone.0090182. eCollection 2014. PubMed PMID: 24594754; PubMed Central PMCID: PMC3971560.
- 44: **Fernández Ó**, Rodríguez-Antigüedad A, Oreja-Guevara C, Garcia-Garcia M, Montalban X; investigadores del Registro Español de Gilenya. [Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya®)]. *Rev Neurol*. 2014 Jan 16;58(2):77-83. Spanish. PubMed PMID:24399624.
- 45: **Fernández O**, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X. Spanish consensus on the use of natalizumab (Tysabri®)-2013.

Neurología. 2015 Jun;30(5):302-14. doi: 10.1016/j.nrl.2013.10.004. Epub 2013 Dec 19. English, Spanish. PubMed PMID: 24360652.

46: **Fernández O**, Fernández V. Evoked potentials are of little use in the diagnosis or monitoring of MS: no. *Mult Scler*. 2013 Dec;19(14):1822-3. doi: 10.1177/1352458513506955. PubMed PMID: 24277733.

47: Oreja-Guevara C, Montalban X, de Andrés C, Casanova-Estruch B, Muñoz-García D, García I, **Fernández Ó**; Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología. [Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología]. *Rev Neurol*. 2013 Oct 16;57(8):359-73. Spanish. PubMed PMID: 24081891.

48: **Fernández Ó**, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de Las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao Mdel M, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Saiz A, Téllez N, Villar LM, Tintoré M; Grupo Post-ECTRIMS. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). *Rev Neurol*. 2013 Sep 1;57(5):217-29. English, Spanish. PubMed PMID:23975528.

49: Baumstarck K, Butzkueven H, **Fernández O**, Flachenecker P, Stecchi S, Idiman E, Pelletier J, Boucekine M, Auquier P. Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. *Health Qual Life Outcomes*. 2013 Jul 29;11:127. doi: 10.1186/1477-7525-11-127. PubMed PMID: 23895207; PubMed Central PMCID: PMC3735484.

50: Oliver-Martos B, Órpez-Zafra T, Urbaneja P, Maldonado-Sanchez R, Leyva L, **Fernández O**. Early development of anti-natalizumab antibodies in MS patients. *J Neurol*. 2013 Sep;260(9):2343-7. doi: 10.1007/s00415-013-6991-2. Epub 2013 Jun 14. PubMed PMID: 23765090.

51: International Multiple Sclerosis Genetics Consortium, Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, Ortiz MA, Pérez J, Damotte V, Booth D, Lopez de Lapuente A, Broer L, Schilling M, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Blaschke P, Buttman M, Chan A, Compston A, Courru-Rebeix I, Dörner T, Epplen JT, **Fernández Ó**, Gerdes LA, Guillot-Noël L, Hartung HP, Hoffjan S, Izquierdo G, Kempainen A, Kroner A, Kubisch C, Kumpfel T, Li SC, Lindenberger U, Lohse P, Lubetzki C, Luessi F, Malhotra S, Mescheriakova J, Montalban X, Papeix C, Paredes LF, Rieckmann P, Steinhagen-Thiessen E, Winkelmann A, Zettl UK, Hintzen R, Vandenbroeck K, Stewart G, Fontaine B, Comabella M, Urcelay E, Matesanz F, Sawcer S, Bertram L, Zipp F. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. *Brain*. 2013 Jun;136(Pt 6):1778-82. doi: 10.1093/brain/awt101. PubMed PMID: 23739915; PubMed Central PMCID: PMC3673463.

52: Fernández O. Integrating the tools for an individualized prognosis in multiple sclerosis. *J Neurol Sci*. 2013 Aug 15;331(1-2):10-3. doi: 10.1016/j.jns.2013.04.021. Epub 2013 May 19. Review. PubMed PMID: 23692966.

53: López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, **Fernández Ó**, Leyva L. Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients. *PLoS One*. 2013 Apr 29;8(4):e62540. doi: 10.1371/journal.pone.0062540. Print 2013. PubMed PMID: 23658636; PubMed Central PMCID: PMC3639207.

54: García-Merino A, **Fernández O**, Montalbán X, de Andrés C, Oreja-Guevara C, Rodríguez-Antigüedad A, Arbizu T; Grupo de Consenso de la Sociedad Española de Neurología. Consensus Statement on medication use in multiple sclerosis by the Spanish Society of

Neurology's study group for demyelinating diseases. *Neurologia*. 2013 Jul-Aug;28(6):375-8. doi: 10.1016/j.nrl.2013.01.009. Epub 2013 May 3. Review. English, Spanish. PubMed PMID: 23643683.

55: Swaminathan B, Cuapio A, Alloza I, Matesanz F, Alcina A, García-Barcina M, Fedetz M, **Fernández O**, Lucas M, Orpez T, Pinto-Medel MJ, Otaegui D, Olascoaga J, Urcelay E, Ortiz MA, Arroyo R, Oksenberg JR, Antigüedad A, Tolosa E, Vandenberg K. Fine mapping and functional analysis of the multiple sclerosis risk gene CD6. *PLoS One*. 2013 Apr 24;8(4):e62376. doi: 10.1371/journal.pone.0062376. Print 2013. PubMed PMID: 23638056; PubMed Central PMCID: PMC3634811.

56: Comabella M, Caminero AB, Malhotra S, Agulló L, **Fernández O**, Reverter F, Vandenberg K, Rodríguez-Antigüedad A, Matesanz F, Izquierdo G, Urcelay E, López-Larios A, Sánchez A, Otero S, Tintoré M, Montalban X. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. *Neurology*. 2013 May 28;80(22):2010-6. doi: 10.1212/WNL.0b013e318294b2d6. Epub 2013 Apr 26. PubMed PMID: 23624563.

57: **Fernández Ó**, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. [Biomarkers in multiple sclerosis]. *Rev Neurol*. 2013 Apr 1;56(7):375-90. Review. Spanish. PubMed PMID: 23520007.

58: **Fernández O**. Best practice in the use of natalizumab in multiple sclerosis. *Ther Adv Neurol Disord*. 2013 Mar;6(2):69-79. doi: 10.1177/1756285612470401. PubMed PMID: 23483450; PubMed Central PMCID: PMC3582310.

59: Baumstarck K, Pelletier J, Butzkueven H, **Fernández O**, Flachenecker P, Idiman E, Stecchi S, Boucekine M, Auquier P; MusiQoL study group. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. *Eur J Neurol*. 2013 Jun;20(6):907-14, e78-9. doi: 10.1111/ene.12087. Epub 2013 Jan 24. PubMed PMID: 23347258.

60: Alcina A, Fedetz M, **Fernández O**, Saiz A, Izquierdo G, Lucas M, Leyva L, García-León JA, Abad-Grau Mdel M, Alloza I, Antigüedad A, Garcia-Barcina MJ, Vandenberg K, Varadé J, de la Hera B, Arroyo R, Comabella M, Montalban X, Petit-Marty N, Navarro A, Otaegui D, Olascoaga J, Blanco Y, Urcelay E, Matesanz F. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. *J Med Genet*. 2013 Jan;50(1):25-33. doi: 10.1136/jmedgenet-2012-101085. Epub 2012 Nov 17. PubMed PMID: 23160276; PubMed Central PMCID: PMC3538279.

61: **Fernandez O**, Berger T, Hartung HP, Putzki N. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. *Expert Rev Clin Pharmacol*. 2012 Nov;5(6):649-65. doi: 10.1586/ecp.12.59. Epub 2012 Nov 13. PubMed PMID: 23146002.

62 : Fernández V, Valls-Sole J, Relova JL, Ragner N, Miralles F, Dinca L, Taramundi S, Costa-Frossard L, Ferrandiz M, Ramió-Torrentà L, Villoslada P, Saiz A, Calles C, Antigüedad A, Alvarez-Cermeño JC, Prieto JM, Izquierdo G, Montalbán X, **Fernández O**. [Recommendations for the clinical use of motor evoked potentials in multiple sclerosis]. *Neurologia*. 2013 Sep;28(7):408-16. doi: 10.1016/j.nrl.2012.07.007. Epub 2012 Sep 18. Review. Spanish. PubMed PMID: 22995526.

63: **Fernández Ó**, Álvarez-Cermeño JC, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Meca-Lallana JE, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Romero-Pinel L, Sanchez F, Téllez N, Tintoré M, Montalban X; Post-ECTRIMS group. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). *Rev Neurol*. 2012 Jun 1;54(11):677-91. Review. English, Spanish. PubMed PMID: 22627749.

- 64: **Fernández O**, Agüera E, Izquierdo G, Millán-Pascual J, Ramió I Torrentà L, Oliva P, Argente J, Berdei Y, Soler JM, Carmona O, Errea JM, Farrés J; Group on Adherence to IFN-1b in Spain. Adherence to interferon  $\beta$ -1b treatment in patients with multiple sclerosis in Spain. *PLoS One*. 2012;7(5):e35600. doi: 10.1371/journal.pone.0035600. Epub 2012 May 16. Erratum in: *PLoS One*. 2012;7(6). doi:10.1371/annotation/35c70f05-8483-4310-aa2a-4665f4842129. Agüera, Javier [corrected Agüera, Eduardo]; Millán-Pascual, Javier [corrected to Millán-Pascual, Jorge]Argente, Javier [corrected to Argente, Joaquin]. PubMed PMID: 22615737; PubMed Central PMCID: PMC3353967.
- 65: Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, Zara I, Pitzalis M, Cavanillas ML, Arroyo R, Zoledziewska M, Marrosu M, **Fernández O**, Leyva L, Alcina A, Fedetz M, Moreno-Rey C, Velasco J, Real LM, Ruiz-Peña JL, Cucca F, Ruiz A, Izquierdo G. Genome-wide association study of multiple Sclerosis confirms a novel locus at 5p13.1. *PLoS One*. 2012;7(5):e36140. doi: 10.1371/journal.pone.0036140. Epub 2012 May 3. PubMed PMID: 22570697; PubMed Central PMCID: PMC3343041.
- 66: de la Concha EG, Cavanillas ML, Cénit MC, Urcelay E, Arroyo R, **Fernández Ó**, Álvarez-Cermeño JC, Leyva L, Villar LM, Núñez C. DRB1\*03:01 haplotypes: differential contribution to multiple sclerosis risk and specific association with the presence of intrathecal IgM bands. *PLoS One*. 2012;7(2):e31018. doi: 10.1371/journal.pone.0031018. Epub 2012 Feb 17. PubMed PMID: 22363536; PubMed Central PMCID: PMC3281895.
- 67: **Fernández O**, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. *J Neurol*. 2012 Sep;259(9):1814-23. PubMed PMID: 22289966; PubMed Central PMCID: PMC3432776.
- 68: Pinto-Medel MJ, García-León JA, Oliver-Martos B, López-Gómez C, Luque G, Arnáiz-Urrutia C, Orpez T, Marín-Bañasco C, Fernández O, Leyva L. The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis. *J Neuroimmunol*. 2012 Feb 29;243(1-2):1-11. doi:10.1016/j.jneuroim.2011.11.008. Epub 2012 Jan 20. PubMed PMID: 22261542.
- 69: Alcina A, Abad-Grau Mdel M, Fedetz M, Izquierdo G, Lucas M, **Fernández O**, Ndagire D, Catalá-Rabasa A, Ruiz A, Gayán J, Delgado C, Arnal C, Matesanz F. Multiple sclerosis risk variant HLA-DRB1\*1501 associates with high expression of DRB1 gene in different human populations. *PLoS One*. 2012;7(1):e29819. doi: 10.1371/journal.pone.0029819. Epub 2012 Jan 13. PubMed PMID: 22253788; PubMed Central PMCID: PMC3258250.
- 70: **Fernández O**. Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis. *J Cent Nerv Syst Dis*. 2012 Aug 29;4:117-33. doi: 10.4137/JCNSD.S8755. Print 2012. PubMed PMID: 23650472; PubMed Central PMCID: PMC3619555.
- 71: Varadé J, Comabella M, Ortiz MA, Arroyo R, **Fernández O**, Pinto-Medel MJ, Fedetz M, Izquierdo G, Lucas M, Gómez CL, Rabasa AC, Alcina A, Matesanz F, Alloza I, Antigüedad A, García-Barcina M, Otaegui D, Olascoaga J, Saiz A, Blanco Y, Montalbán X, Vandebroek K, Urcelay E. Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. *Mult Scler*. 2012 Jul;18(7):959-65. doi: 10.1177/1352458511432741. Epub 2011 Dec 22. PubMed PMID: 22194214.
- 72: Cantó E, Reverter F, Morcillo-Suárez C, Matesanz F, **Fernández O**, Izquierdo G, Vandebroek K, Rodríguez-Antigüedad A, Urcelay E, Arroyo R, Otaegui D, Olascoaga J, Saiz A, Navarro A, Sanchez A, Domínguez C, Caminero A, Horga A, Tintoré M, Montalban X, Comabella M. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. *Mult Scler*. 2012 Jul;18(7):983-90. doi: 10.1177/1352458511433063. Epub 2011 Dec 19. PubMed PMID: 22183936.

73: Alloza I, Otaegui D, de Lapuente AL, Antigüedad A, Varadé J, Núñez C, Arroyo R, Urcelay E, **Fernández O**, Leyva L, Fedetz M, Izquierdo G, Lucas M, Oliver-Martos B, Alcina A, Saiz A, Blanco Y, Comabella M, Montalban X, Olascoaga J, Matesanz F, Vandebroek K. ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. *Genes Immun.* 2012 Apr;13(3):253-7. doi: 10.1038/gene.2011.81. Epub 2011 Dec 1. PubMed PMID: 22130326.

74: **Fernández O**, Vermersch P. From the fundamentals of multiple sclerosis to clinical management. *J Neurol Sci.* 2011 Dec;311 Suppl 1:S1-2. PubMed PMID: 24459712.

75: **Fernández O**, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Arbizu T, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Montalbán X. Spanish consensus on the use of natalizumab (Tysabri®)--2011. *Neurologia.* 2012 Sep;27(7):432-41. Epub 2011 Nov 9. English, Spanish. PubMed PMID: 22078648.

76: **Fernández O**, Fernández V, Baumstarck-Barrau K, Muñoz L, Gonzalez Alvarez Mdel M, Arrabal JC, León A, Alonso A, López-Madróna JC, Bustamante R, Luque G, Guerrero M, di Cantogno EV, Auquier P; MusiQoL study group of Spain. Validation of the spanish version of the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire. *BMC Neurol.* 2011 Oct 18;11:127. doi: 10.1186/1471-2377-11-127. PubMed PMID: 22013975; PubMed Central PMCID: PMC3206836.

77: Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E, **Fernández O**, Drulovic J, García-Merino A, Martinelli Boneschi F, Chan A, Vandebroek K, Navarro A, Bustamante MF, Río J, Akkad DA, Giacalone G, Sánchez AJ, Leyva L, Alvarez-Lafuente R, Zettl UK, Oksenberg J, Montalban X, Comabella M. IL28B polymorphisms are not associated with the response to interferon- $\beta$  in multiple sclerosis. *J Neuroimmunol.* 2011 Oct 28;239(1-2):101-4. doi: 10.1016/j.jneuroim.2011.08.004. Epub 2011 Sep 1. PubMed PMID: 21889215.

78: **Fernández O**, Fernández V, Guerrero M, León A, López-Madróna JC, Alonso A, Bustamante R, Tamayo JA, Romero F, Bravo M, Luque G, García L, Sanchís G, San Roman C, Romero M, Papais-Alvarenga M, de Ramon E. Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. *Mult Scler.* 2012 Mar;18(3):372-6. doi: 10.1177/1352458511421917. Epub 2011 Aug 30. PubMed PMID: 21878452.

79: **Fernández O**, Baumstarck-Barrau K, Simeoni MC, Auquier P; MusiQoL study group. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. *Mult Scler.* 2011 Oct;17(10):1238-49. doi: 10.1177/1352458511407951. Epub 2011 Jun 13. PubMed PMID: 21669936.

80: Abaira V, Alvarez-Cermeño JC, Arroyo R, Cámara C, Casanova B, Cubillo S, de Andrés C, Espejo C, **Fernández O**, Ferrer J, Figueredo MA, García-Merino A, García-Sánchez MI, García-Trujillo JA, Gómez M, González-Oria C, Gosis A, Izquierdo G, Jiménez J, López-Trascasa M, Montalbán X, Moreno MJ, Muñoz D, Nuñez V, Muriel A, Navarro J, Olascoaga J, Oreja-Guevara C, Prada A, Ramil E, Ramo-Tello C, Rodríguez C, Rodríguez E, Rodríguez-Frías F, Rodríguez-Antigüedad A, Rodríguez-Molina JJ, Ruiz E, Saiz A, Sarasola E, Simó M, Yagüe J, Villar LM. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. *J Immunol Methods.* 2011 Aug 31;371(1-2):170-3. doi: 10.1016/j.jim.2011.06.009. Epub 2011 Jun 17. PubMed PMID: 21704629.

81: Vandebroek K, Alvarez J, Swaminathan B, Alloza I, Matesanz F, Urcelay E, Comabella M, Alcina A, Fedetz M, Ortiz MA, Izquierdo G, **Fernández O**, Rodríguez-Ezpeleta N, Matute C, Caillier S, Arroyo R, Montalban X, Oksenberg JR, Antigüedad A, Aransay A. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. *Genes Immun.* 2012 Jan;13(1):21-8. doi: 10.1038/gene.2011.44. Epub 2011 Jun 30. PubMed PMID: 21716315.

82: López-Gómez C, **Fernández O**, García-León JA, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Suardiáz M, García-Trujillo L, Guijarro-Castro C, Benito-León J, Prat I, Varadé J, Álvarez-Lafuente R, Urcelay E, Leyva L. TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis. *PLoS One*. 2011;6(7):e21766. doi: 10.1371/journal.pone.0021766. Epub 2011 Jul 21. PubMed PMID: 21814551; PubMed Central PMCID: PMC3140982.

82: Villegas E, Santiago O, Carrillo JA, Sorlózano A, Guerrero M, **Fernández O**, Gutiérrez J. Low intrathecal immune response of anti-EBNA-1 antibodies and EBV DNA from multiple sclerosis patients. *Diagn Microbiol Infect Dis*. 2011 May;70(1):85-90. doi: 10.1016/j.diagmicrobio.2010.11.013. Epub 2011 Mar 9. PubMed PMID: 21388770.

83: Oliver B, **Fernández O**, Orpez T, Alvarenga MP, Pinto-Medel MJ, Guerrero M, León A, López-Madróna JC, Maldonado-Sánchez R, García-León JA, Luque G, Fernández V, Leyva L. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. *Mult Scler*. 2011 Mar;17(3):368-71. doi: 10.1177/1352458510385508. Epub 2010 Dec 21. PubMed PMID: 21177326.

84: **Fernández O**. Oral laquinimod treatment in multiple sclerosis. *Neurologia*. 2011 Mar;26(2):111-7. doi: 10.1016/j.nrl.2010.07.027. Review. English, Spanish. PubMed PMID: 21163185.

85: Oliver-Martos B, Orpez T, Pinto-Medel MJ, Mayorga C, García-León JA, Maldonado-Sánchez R, Suardiáz M, Guerrero M, Luque G, Leyva L, **Fernández O**. Gene expression in IFN $\beta$  signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients. *J Neuroimmunol*. 2011 Jan;230(1-2):153-9. doi: 10.1016/j.jneuroim.2010.10.033. Epub 2010 Nov 24. PubMed PMID: 21106255.

86: **Fernández O**, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madróna JC, Leyva L, Oliver B, de Ramón E, Luque G, Fernández V. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. *Mult Scler*. 2011 Feb;17(2):192-7. doi: 10.1177/1352458510385507. Epub 2010 Nov 18. PubMed PMID: 21088044.

87: Blanco-Kelly F, Alvarez-Lafuente R, Alcina A, Abad-Grau MM, de Las Heras V, Lucas M, de la Concha EG, **Fernández O**, Arroyo R, Matesanz F, Urcelay E. Members 6B and 14 of the TNF receptor superfamily in multiple sclerosis predisposition. *Genes Immun*. 2011 Mar;12(2):145-8. doi: 10.1038/gene.2010.42. Epub 2010 Oct 21. PubMed PMID: 20962851.

88: Cavanillas ML, **Fernández O**, Comabella M, Alcina A, Fedetz M, Izquierdo G, Lucas M, Cénit MC, Arroyo R, Vandebroek K, Alloza I, García-Barcina M, Antigüedad A, Leyva L, Gómez CL, Olascoaga J, Otaegui D, Blanco Y, Saiz A, Montalbán X, Matesanz F, Urcelay E. Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. *Genes Immun*. 2011 Mar;12(2):110-5. doi: 10.1038/gene.2010.52. Epub 2010 Oct 14. PubMed PMID:20944657.

89: García Merino A, **Fernández O**, Montalbán X, de Andrés C, Arbizu T. [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy]. *Neurologia*. 2010 Jul-Aug;25(6):378-90. Spanish. PubMed PMID: 20738958.

90: Blanco-Kelly F, Matesanz F, Alcina A, Teruel M, Díaz-Gallo LM, Gómez-García M, López-Nevot MA, Rodrigo L, Nieto A, Cardeña C, Alcain G, Díaz-Rubio M, de la Concha EG, **Fernández O**, Arroyo R, Martín J, Urcelay E. CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility. *PLoS One*. 2010 Jul 12;5(7):e11520. doi: 10.1371/journal.pone.0011520. Erratum in: *PLoS One*. 2010;5(8). doi: 10.1371/annotation/4d830d1b-46ff-4d72-b577-6a3765d335fc. PubMed PMID: 20634952; PubMed Central PMCID: PMC2902513.

91: Alcina A, Vandebroek K, Otaegui D, Saiz A, Gonzalez JR, **Fernandez O**, Cavanillas ML, Cénit MC, Arroyo R, Alloza I, García-Barcina M, Antigüedad A, Leyva L, Izquierdo G, Lucas M, Fedetz M, Pinto-Medel MJ, Olascoaga J, Blanco Y, Comabella M, Montalban X, Urcelay E, Matesanz F. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. *Genes Immun*. 2010 Jul;11(5):439-45. doi: 10.1038/gene.2010.30. Epub 2010 May 27. PubMed PMID: 20508602.

92: Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, Olascoaga J, Cénit MC, de las Heras V, Barcina MG, Arroyo R, Alcina A, **Fernandez O**, Antigüedad A, Urcelay E, Vandebroek K. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. *J Neuroimmunol*. 2010 Jun;223(1-2):100-3. doi: 10.1016/j.jneuroim.2010.03.020. Epub 2010 Apr 28. PubMed PMID: 20430450.

93: Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, **Fernandez O**. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. *Eur J Clin Microbiol Infect Dis*. 2010 Jul;29(7):857-66. doi: 10.1007/s10096-010-0940-0. Epub 2010 Apr 29. PubMed PMID: 20428908.

94: **Fernández O**, Fernández V, Arbizu T, Izquierdo G, Bosca I, Arroyo R, García Merino JA, de Ramón E; Novo Group. Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). *J Neurol*. 2010 Sep;257(9):1500-7. doi: 10.1007/s00415-010-5560-1. Epub 2010 Apr 10. PubMed PMID: 20383518.